Anna Kalff

1.0k total citations
46 papers, 661 citations indexed

About

Anna Kalff is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Anna Kalff has authored 46 papers receiving a total of 661 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hematology, 28 papers in Molecular Biology and 21 papers in Oncology. Recurrent topics in Anna Kalff's work include Multiple Myeloma Research and Treatments (36 papers), Protein Degradation and Inhibitors (13 papers) and Peptidase Inhibition and Analysis (10 papers). Anna Kalff is often cited by papers focused on Multiple Myeloma Research and Treatments (36 papers), Protein Degradation and Inhibitors (13 papers) and Peptidase Inhibition and Analysis (10 papers). Anna Kalff collaborates with scholars based in Australia, United States and New Zealand. Anna Kalff's co-authors include Andrew Spencer, Tiffany Khong, Sridurga Mithraprabhu, Annie Chow, Andrew Grigg, Jane S. Hocking, Hang Quach, Krystal Bergin, John Reynolds and Brian G.M. Durie and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Infectious Diseases.

In The Last Decade

Anna Kalff

42 papers receiving 653 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Kalff Australia 11 477 436 238 120 77 46 661
Weiwei Sui China 12 373 0.8× 355 0.8× 232 1.0× 121 1.0× 113 1.5× 82 575
Alberto Rocci Italy 14 373 0.8× 417 1.0× 170 0.7× 87 0.7× 99 1.3× 32 661
J. Erika Haydu United States 8 407 0.9× 405 0.9× 123 0.5× 91 0.8× 289 3.8× 12 799
Paolo Ditonno Italy 9 258 0.5× 239 0.5× 201 0.8× 69 0.6× 25 0.3× 15 470
Matthew S. Zabriskie United States 9 416 0.9× 307 0.7× 170 0.7× 70 0.6× 301 3.9× 24 720
Marielle Chiron France 12 321 0.7× 299 0.7× 440 1.8× 61 0.5× 81 1.1× 44 745
Wendy L. See United States 9 248 0.5× 326 0.7× 102 0.4× 121 1.0× 179 2.3× 20 557
Aleksandra Rizo United States 10 337 0.7× 314 0.7× 193 0.8× 52 0.4× 215 2.8× 28 655
Cathy Quelen France 14 157 0.3× 395 0.9× 110 0.5× 199 1.7× 115 1.5× 20 627

Countries citing papers authored by Anna Kalff

Since Specialization
Citations

This map shows the geographic impact of Anna Kalff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Kalff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Kalff more than expected).

Fields of papers citing papers by Anna Kalff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Kalff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Kalff. The network helps show where Anna Kalff may publish in the future.

Co-authorship network of co-authors of Anna Kalff

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Kalff. A scholar is included among the top collaborators of Anna Kalff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Kalff. Anna Kalff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Webb, Andrew I., et al.. (2024). Drug induced haemolytic anaemia in the era of daratumumab. Pathology. 56. S102–S102.
2.
Shore‐Lorenti, Catherine, Roger Zebaze, Peter G. Kerr, et al.. (2023). A Novel RUNX1 Genetic Variant Identified in a Young Male with Severe Osteoporosis. JBMR Plus. 7(9). e10791–e10791.
3.
Kalff, Anna, Peter Mollee, P. Joy Ho, et al.. (2023). The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal. 53(5). 819–824. 6 indexed citations
4.
Turner, Robert, Hang Quach, Noemi Horvath, et al.. (2023). Response adaptive salvage with KTd and ASCT for functional high‐risk multiple myeloma—The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial. British Journal of Haematology. 202(3). 530–538. 3 indexed citations
5.
6.
Turner, Rose, et al.. (2022). The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice. Frontiers in Oncology. 12. 820605–820605. 4 indexed citations
7.
8.
Kalff, Anna, Tiffany Khong, P. Joy Ho, et al.. (2021). Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14). Haematologica. 107(1). 321–325. 1 indexed citations
9.
10.
Mithraprabhu, Sridurga, Tiffany Khong, Anna Kalff, et al.. (2019). Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients. Leukemia. 33(8). 2022–2033. 46 indexed citations
11.
Raith, Eamon, Joshua Ihle, Jennifer Jamieson, Anna Kalff, & Julian J. Bosco. (2018). Idiopathic systemic capillary leak syndrome presenting as septic shock: A case report. Heart & Lung. 47(4). 425–428. 7 indexed citations
12.
Löw, Michael, Pasquale L. Fedele, Anna Kalff, et al.. (2018). DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma. Leukemia & lymphoma. 59(12). 2842–2846. 12 indexed citations
13.
Nair, Anish, Patricia Walker, Anna Kalff, et al.. (2017). Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma. Bone Marrow Transplantation. 52(6). 839–845. 4 indexed citations
14.
Hocking, Jane S., et al.. (2016). Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies. Cancer Biology and Medicine. 13(2). 215–225. 30 indexed citations
15.
Mithraprabhu, Sridurga, Anna Kalff, Annie Chow, Tiffany Khong, & Andrew Spencer. (2014). Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 9(11). 1511–1520. 144 indexed citations
16.
17.
Bryant, Adam, Ian Nivison‐Smith, Anna Kalff, et al.. (2013). Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients. Bone Marrow Transplantation. 49(1). 17–23. 10 indexed citations
18.
Kalff, Anna & Andrew Spencer. (2012). The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer Journal. 2(9). e89–e89. 84 indexed citations
19.
Quach, Hang, Anna Kalff, & Andrew Spencer. (2012). Lenalidomide in multiple myeloma: Current status and future potential. American Journal of Hematology. 87(12). 1089–1095. 24 indexed citations
20.
Kalff, Anna, et al.. (2010). The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adults. British Journal of Haematology. 149(5). 768–774. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Weiwei Sui Breakdown of academic impact, for papers by Alberto Rocci Breakdown of academic impact, for papers by J. Erika Haydu Breakdown of academic impact, for papers by Paolo Ditonno Breakdown of academic impact, for papers by Matthew S. Zabriskie Breakdown of academic impact, for papers by Marielle Chiron Breakdown of academic impact, for papers by Wendy L. See Breakdown of academic impact, for papers by Aleksandra Rizo Breakdown of academic impact, for papers by Cathy Quelen
Rankless by CCL
2026